Article

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

2026-08-04

Abstract excerpt

Epithelioid sarcoma (EpS) is an ultra-rare, aggressive soft tissue sarcoma (STS) driven by INI1 loss and consequent hyperactivation of the chromatin-modifying enzyme EZH2. Although the EZH2 inhibitor tazemetostat has shown clinical activity, responses remain limited, highlighting the need for improved treatment strategies. Here, using two in-house generated patient-derived xenograft models and matched cell lines d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3646890-4e02-58f6-9dde-106bd94b127a
DOI: 10.64898/2026.08.04.742011

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationDOI 10.64898/2026.08.04.742011Read

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combinationSemantic proximity Read

Targeting epigenetics in sarcomas through EZH2 inhibitionSemantic proximity Read

Genetic and epigenetic characterization of sarcoma stem cells across subtypes identifies EZH2 as a therapeutic targetSemantic proximity Read

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read

Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic TargetSemantic proximity Read

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.Semantic proximity Read

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesisSemantic proximity Read

Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, RespectivelySemantic proximity Read

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasSemantic proximity Read

Class I Histone Deacetylases (HDAC) Critically Contribute to Ewing Sarcoma PathogenesisSemantic proximity Read

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.Semantic proximity Read

Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and increased expression of transposable elements and viral response pathwaysSemantic proximity Read